Want to see HK:2367 full AI Analyst Report?
2367 Stock Chart & Stats
HK$28.76
HK$0.10(0.22%)
At close: 4:00 PM EST
HK$28.76
HK$0.10(0.22%)
Day’s Range― - ―
52-Week RangeHK$20.60 - HK$42.68
Previous CloseN/A
Volume2.50M
Average Volume (3M)3.08M
Market Cap
HK$21.76B
Enterprise ValueHK$19.45B
Total Cash (Recent Filing)HK$7.39B
Total Debt (Recent Filing)HK$12.25M
Price to Earnings (P/E)11.3
Beta1.04
Next Earnings
Mar 29, 2027EPS Estimate
1.03Next Dividend Ex-DateN/A
Dividend Yield2.98%
Share Statistics
EPS (TTM)1.56
Shares Outstanding1,061,704,000
10 Day Avg. Volume4,283,809
30 Day Avg. Volume3,077,287
Financial Highlights & Ratios
PEG Ratio-1.27
Price to Book (P/B)3.19
Price to Sales (P/S)5.73
P/FCF Ratio21.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$40.59Price Target Upside41.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)1.82
Revenue Forecast (FY)HK$6.06B
Bulls Say, Bears Say
Bulls Say
Exceptional ProfitabilityVery high gross, net, and operating margins show that the core business currently converts sales into substantial profit. This profitability provides internal funding for research, development, and commercialization while offering a cushion against moderate cost or demand pressure over the next several quarters.
Very Low LeverageDebt-to-equity of around 0.1% leaves the company with substantial financial flexibility and limited balance-sheet strain. A conservative capital structure can support continued investment and help the business absorb weaker demand without relying heavily on refinancing or added interest expense.
Strong Cash GenerationStrong operating cash flow and free cash flow, with 2025 free cash flow growth still positive, indicate meaningful cash generation behind reported earnings. This supports reinvestment and financial resilience, although the roughly 0.78x free-cash-flow-to-net-income coverage warrants monitoring.
Bears Say
Revenue ContractionAnnual revenue fell 12.0% in 2025 after several years of rapid expansion, indicating that demand momentum has reversed. If this contraction persists, it can reduce operating scale, limit investment capacity, and make restoring prior growth rates more difficult over the next several quarters.
Earnings And Margin PressureNet income declined versus 2024 and margins compressed from prior peak levels, showing that the slowdown is affecting profitability as well as sales. Continued earnings pressure would weaken internally generated growth capital and reduce the durability of the company's previously exceptional returns.
Variable Cash ConversionFree cash flow covered roughly 0.78x net income in 2025, below the prior year's conversion, while coverage was unusually weak in 2020–2021. This variability means reported profits may not consistently translate into deployable cash across the business cycle.
Giant Biogene Holding Co. Ltd. News
2367 FAQ
What was Giant Biogene Holding Co. Ltd.’s price range in the past 12 months?
Giant Biogene Holding Co. Ltd. lowest stock price was HK$20.60 and its highest was HK$42.68 in the past 12 months.
What is Giant Biogene Holding Co. Ltd.’s market cap?
Giant Biogene Holding Co. Ltd.’s market cap is HK$21.76B.
When is Giant Biogene Holding Co. Ltd.’s upcoming earnings report date?
Giant Biogene Holding Co. Ltd.’s upcoming earnings report date is Mar 29, 2027 which is in 154 days.
How were Giant Biogene Holding Co. Ltd.’s earnings last quarter?
Giant Biogene Holding Co. Ltd. released its earnings results on Aug 18, 2026. The company reported HK$1.04 earnings per share for the quarter, beating the consensus estimate of HK$1.029 by HK$0.012.
Is Giant Biogene Holding Co. Ltd. overvalued?
According to Wall Street analysts Giant Biogene Holding Co. Ltd.’s price is currently Undervalued.
Does Giant Biogene Holding Co. Ltd. pay dividends?
Giant Biogene Holding Co. Ltd. pays a Notavailable dividend of HK$1.389 which represents an annual dividend yield of 2.98%. See more information on Giant Biogene Holding Co. Ltd. dividends here
What is Giant Biogene Holding Co. Ltd.’s EPS estimate?
Giant Biogene Holding Co. Ltd.’s EPS estimate is 1.03.
How many shares outstanding does Giant Biogene Holding Co. Ltd. have?
Giant Biogene Holding Co. Ltd. has 1,061,704,000 shares outstanding.
What happened to Giant Biogene Holding Co. Ltd.’s price movement after its last earnings report?
Giant Biogene Holding Co. Ltd. reported an EPS of HK$1.04 in its last earnings report, beating expectations of HK$1.029. Following the earnings report the stock price went down -5.641%.
Which hedge fund is a major shareholder of Giant Biogene Holding Co. Ltd.?
Currently, no hedge funds are holding shares in HK:2367
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Giant Biogene Holding Co. Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.16%
12-Months-Change
Fundamentals
Return on Equity
17.22%
Trailing 12-Months
Asset Growth
-4.25%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Giant Biogene Holding Co. Ltd.
Giant Biogene Holding Co., Ltd. operates as an investment holding entity, primarily engaged in the research, development, production, and sale of beauty and wellness products based on bioactive materials throughout the People's Republic of China. The company also manufactures functional foods leveraging rare ginsenosides technology and provides medical devices. Its diverse product range, which includes specialized skincare, medical dressings, and nutritional supplements, is marketed predominantly under brand names such as Comfy, Collgene, Keyu, Kehen, Kefuping, Leeyen, SKIGIN, and Shengan. Established in 2000, Giant Biogene Holding Co., Ltd. maintains its headquarters in Xi'an, PRC.
2367 Stock 12 Month Forecast
Average Price Target
HK$40.59
▲(41.12% Upside)
Technical Analysis
Hengan International Group Co
―
Ming Fai International Holdings
―
Natural Beauty Bio-Technology
―
Shanghai Chicmax Cosmetics Co., Ltd. Class H
―
Blue Moon Group Holdings Ltd.
―